Cargando…

Temozolomide therapy: Focus on patients with pituitary carcinoma

Detalles Bibliográficos
Autor principal:	Curtò, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898097/ https://www.ncbi.nlm.nih.gov/pubmed/27365946 http://dx.doi.org/10.4103/0976-3147.181478

Ejemplares similares

Temozolomide in aggressive pituitary adenomas and carcinomas
por: Ortiz, Leon D., et al.
Publicado: (2012)

Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review
por: Curtò, Lorenzo, et al.
Publicado: (2010)

A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment
por: Morokuma, Haruko, et al.
Publicado: (2012)

Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
por: Das, Liza, et al.
Publicado: (2021)

Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis
por: Luo, Mei, et al.
Publicado: (2021)

Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
por: Bruno, Oscar D., et al.
Publicado: (2015)

NICE verdict on Temozolomide: where next?
por: Brada, M
Publicado: (2002)

Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
por: Syro, Luis V., et al.
Publicado: (2018)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

Commentary on “Co-Occurrence of Pituitary Adenoma With Suprasellar and Olfactory Groove Meningiomas”
por: Curtò, Lorenzo, et al.
Publicado: (2017)

A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma
por: Misir Krpan, Ana, et al.
Publicado: (2017)

SUN-272 Significant Response to Temozolomide in Two Aggressively Growing Pituitary Adenomas
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2020)

Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?
por: Said, Medhat M., et al.
Publicado: (2023)

Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review
por: Moisi, Marc, et al.
Publicado: (2016)

MON-406 Two Cases of Aggressive Corticotroph Pituitary Tumors Treated with Capecitabine and Temozolomide
por: Tateno, Tae, et al.
Publicado: (2019)

Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review
por: Ishida, Atsushi, et al.
Publicado: (2022)

Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature
por: Kurowska, Maria, et al.
Publicado: (2015)

A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors
por: Cui, Jie, et al.
Publicado: (2022)

MON-407 Tumor Control after Radiotherapy and Temozolomide in a Cushing's Disease Patient with Giant Aggressive Pituitary Tumor
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2021)

Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
por: Dai, Congxin, et al.
Publicado: (2021)

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
por: Fujimaki, Takamitsu, et al.
Publicado: (2007)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
por: Asimakopoulou, Athina, et al.
Publicado: (2014)

Epithelial Ovarian Cancer: Focus on Targeted Therapy
por: Markman, M., et al.
Publicado: (2010)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

The NETting of pituitary adenoma: a gland illusion
por: Ho, Ken K. Y., et al.
Publicado: (2022)

Markers of Aggressiveness in Pituitary Tumors: Update and Perspectives
por: Bioletto, Fabio, et al.
Publicado: (2022)

Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide
por: Gilbert, Mark R, et al.
Publicado: (2007)

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide
por: Ma, Jun, et al.
Publicado: (2023)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
por: Das, Liza, et al.
Publicado: (2021)

A Pituitary Carcinoma Patient With Cerebrospinal Fluid Dissemination Showing a Good Response to Temozolomide Combined With Whole-Brain and Spinal Cord Radiotherapy: A Case Report and Literature Review
por: Du, Peng, et al.
Publicado: (2022)

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
por: Wen, Patrick Yung, et al.
Publicado: (2020)

Role of the Hypothalamic–Pituitary–Adrenal Axis in Health and Disease
por: DeMorrow, Sharon
Publicado: (2018)

The Surgical Odyssey: Romania’s Contributions to Pituitary Gland Procedures
por: Toader, Corneliu, et al.
Publicado: (2023)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Seeding of a Pituitary Adenoma or Atypical Pituitary Carcinoma?
por: Krueger, Evan M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jl6v1m46r168focfhcoqm3l0cq